Advertisement

Reactions Weekly

, Volume 1766, Issue 1, pp 158–158 | Cite as

Ibrutinib/venetoclax

Various toxicities: 4 case reports
Case report
  • 14 Downloads

In a case series of 4 patients, three adults (one woman and two men) in their 50s-60s and an elderly man [exact age at the time of reaction onset not clearly stated] were described, who developed neutropenia, lung infection, herpes infection or thrombocytopenia during treatment with venetoclax for chronic lymphocytic leukaemia (CLL). Additionally, the woman developed arrhythmia and diarrhoea during treatment with ibrutinib for CLL [routes, time to reaction onsets not stated; not all frequencies stated].

Patient 1: The elderly man developed neutropenia and lung infection following treatment with venetoclax. He was diagnosed with CLL in 1999 (at the age of 51-years). In April 2011 (at the age of 63 years), he underwent allogeneic haematopoietic stem cell transplantation (alloHCT). One month following alloHCT, he presented with fourth relapse, which was treated with rituximab and donor lymphocyte infusions. Further relapses were treated with ofatumumab plus dexamethasone, idelalisib plus...

Reference

  1. Al-Sawaf O, et al. Venetoclax plus rituximab or obinutuzumab after allogeneic hematopoietic stem cell transplantation in chronic lymphocytic leukemia. Haematologica 104: e224-e226, No. 5, 30 Apr 2019. Available from: URL: http://doi.org/10.3324/haematol.2018.212837 - Germany

Copyright information

© Springer International Publishing AG 2019

Personalised recommendations